advertisement
Abstract #15667 Published in IGR 2-3
Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery
Rainer G; Menapace R; Findl O; Georgopoulos M; Kiss B; Heinze GEye 2000; 14: 757-760
PURPOSE: To compare the effectiveness of 2% dorzolamide and 0.5% apraclonidine on intraocular pressure (IOP) following phacoemulsification cataract surgery. METHODS: This prospective, randomized study comprised 54 eyes of 27 consecutive patients with age-related cataract, scheduled for cataract surgery in both eyes. In each patient the eye with the higher degree of cataract was randomly assigned to receive one drop of either dorzolamide or apraclonidine immediately after surgery. The fellow eye was operated on later and received the other treatment. Cataract surgery was performed with a superior 6.0-mm sutureless frown incision, phacoemulsification and implantation of a three-piece PMMA intraocular lens. The IOP was measured pre-operatively as well as sic hours and 20-24 hours and one week postoperatively. RESULTS: The mean preoperative IOP was not significantly different between the groups (dorzolamide group, 14.9 ± 2.3 mmHg; apraclonidine group, 14.6 ± 2.5 mmHg; p = 0.450). At six hours postoperatively, the mean IOP was significantly lower in the dorzolamide than in the apraclonidine group (15.6 ± 3.9 mmHg versus 18.0 ± 4.0 mmHg; p < 0.001). An IOP increase of more than 5 mmHg at six hours postoperatively occurred in three (12%) eyes in the dorzolamide group and in nine (36%) eyes in the apraclonidine group (p = 0.034). At 20-24 hours and one week postoperatively, no difference was found between the groups. CONCLUSIONS: Two percent dorzolamide is more effective than 0.5% apraclonidine in preventing the early postoperative IOP increase following phacoemulsification cataract surgery.
Dr. G. Rainer, Department of Ophthalmology, University of Vienna, Vienna, Austria. georg.rainer@akh-wien.ac.at
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
12.12.3 Phacoemulsification (Part of: 12 Surgical treatment > 12.12 Cataract extraction)
